We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Amarin (AMRN - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Amarin is one of 998 companies in the Medical group. The Medical group currently sits at #6 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Amarin is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for AMRN's full-year earnings has moved 57% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, AMRN has returned 36.6% so far this year. At the same time, Medical stocks have lost an average of 2.3%. This shows that Amarin is outperforming its peers so far this year.
GSK (GSK - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 20.8%.
For GSK, the consensus EPS estimate for the current year has increased 5.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Amarin belongs to the Medical - Biomedical and Genetics industry, which includes 502 individual stocks and currently sits at #78 in the Zacks Industry Rank. On average, this group has lost an average of 0.6% so far this year, meaning that AMRN is performing better in terms of year-to-date returns. GSK is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to Amarin and GSK as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Amarin (AMRN - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Amarin is one of 998 companies in the Medical group. The Medical group currently sits at #6 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Amarin is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for AMRN's full-year earnings has moved 57% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, AMRN has returned 36.6% so far this year. At the same time, Medical stocks have lost an average of 2.3%. This shows that Amarin is outperforming its peers so far this year.
GSK (GSK - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 20.8%.
For GSK, the consensus EPS estimate for the current year has increased 5.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Amarin belongs to the Medical - Biomedical and Genetics industry, which includes 502 individual stocks and currently sits at #78 in the Zacks Industry Rank. On average, this group has lost an average of 0.6% so far this year, meaning that AMRN is performing better in terms of year-to-date returns. GSK is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to Amarin and GSK as they could maintain their solid performance.